# colorectal cancer - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 62323
- Completion tokens: 26746
- Reasoning tokens: 0
- Total tokens: 89069
- API requests reported: 5
- Elapsed seconds: 231.696
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 3/5; original repeat 5; model vendor: OpenAI

---
## Data-quality and statistical context

This is a **prognostic survival analysis**, so HR values describe association with overall-survival hazard, not differential expression. An HR > 1 is risk-associated and an HR < 1 is protective-associated in this cohort; it does **not** establish that the gene is upregulated or causally drives mortality.

The **input/uploaded** dataset contains **100 unique genes represented by 209 retained rows**, including **53 genes/probe groups with duplicates**. There are **54 risk-associated and 46 protective-associated genes**. Eight genes have FDR ≤ 0.01, 71 have FDR ≤ 0.05, and all 100 have nominal P ≤ 0.05. Direction conflicts are present for **DCBLD2, LOC101928747|RBMX|SNORD61, and BCL2L14**, and several probe-level or composite annotations are not unambiguous gene measurements. Therefore, the results provide a strong internal prognostic signal but require probe-level and independent-cohort verification.

**External/independent statistical validation was not performed.** The supplied pathway, interaction, tissue, disease, and literature records are contextual evidence and are not replication statistics or newly computed enrichment results.

## 1. Overall biological interpretation

The survival-associated profile is consistent with several interacting features of colorectal tumor biology:

1. **A risk-associated stromal, extracellular-matrix, adhesion, and signaling phenotype**, represented by INHBB, DCBLD2, ITGBL1, TPM4, ABL2, PTPN14, NT5E, MSLN, and SCEL.
2. **Loss of intestinal epithelial differentiation**, suggested by protective associations for CDX2, CDX1, MYO5B, LGALS4, and related epithelial or trafficking genes.
3. **Metabolic and mitochondrial state differences**, with protective associations for ATP23, NDUFA9, CS, COA3, ATP5G1, and OGDHL, together with protective glycolytic or amino-acid-metabolism genes such as GLYCTK, MCCC2, ILVBL, and ASL.
4. **Possible immune-microenvironment and purinergic-signaling involvement**, particularly through NT5E, LGALS9, CCL15, TAPBPL, and CCDC134.
5. **Cytoskeletal, microtubule-organizing, and cell-motility biology**, supported by TPM4, NIN, MAP1B, ABL2, GJB6, and the retrieved microtubule-anchoring annotation.

The most defensible model is therefore not a single pathway but a **prognostic state combining reduced epithelial differentiation and metabolic competence with increased invasive, stromal, signaling, and potentially immunomodulatory features**. This remains an association-based interpretation; the current data do not demonstrate causality, cellular origin, or treatment response.

## 2. Core biological programs

### Program 1: Extracellular matrix, adhesion, and invasive tumor–stroma signaling

- **Association:** Predominantly risk-associated.
- **Supporting genes:** **INHBB** HR 1.433, FDR 0.001093; **DCBLD2** HR 1.408, FDR 0.008647, although its duplicate rows show a direction conflict; **ITGBL1** HR 1.299, FDR 0.03061; **TPM4** HR 1.364, FDR 0.00891; **PTPN14** HR 1.362, FDR 0.02501; **ABL2** HR 1.301, FDR 0.02757; **ADAMTS18** HR 1.263, FDR 0.04681; and **SCEL** HR 1.254, FDR 0.03939.
- **Relevant standardized pathways:** GO extracellular matrix organization, cell-substrate adhesion, actin cytoskeleton organization, and focal-adhesion-related processes would be appropriate conceptual frameworks. The supplied batch also identified regulation of phospholipase C activity, but this was an annotation recurrence rather than a newly calculated enrichment statistic.
- **Interpretation:** The combination of matrix-associated genes, cytoskeletal components, and intracellular adhesion/signaling regulators is compatible with altered cell–matrix attachment, remodeling of the local extracellular environment, and increased migratory or invasive potential. INHBB has particularly strong direct prognostic support in the **input/uploaded** cohort and is also supported by a colorectal-cancer literature record reporting high INHBB expression with poor prognosis and malignant phenotypes (Europe PMC **PMID 41992239**).
- **Evidence strength:** **Supported hypothesis** from multiple internally concordant genes, with disease/literature plausibility.
- **Limitations:** The genes may reflect tumor-cell invasion, fibroblast abundance, smooth-muscle or vascular components, or overall tumor purity. DCBLD2 has unresolved duplicate-row directionality. No **external/independent** survival statistic or functional assay was supplied.

### Program 2: Intestinal epithelial differentiation and epithelial integrity

- **Association:** Predominantly protective-associated.
- **Supporting genes:** **CDX2** HR 0.7478, FDR 0.0355; **CDX1** HR 0.7809, FDR 0.05735; **MYO5B** HR 0.7483, FDR 0.02823; **LGALS4** HR 0.7712, FDR 0.05123; **RAB11FIP4** HR 0.7361, FDR 0.03294; and **CCL15-CCL14|CCL15** HR 0.7528, FDR 0.0355.
- **Relevant standardized pathways:** GO intestinal epithelial cell differentiation, epithelial cell development, apical junction organization, and vesicle-mediated transport; Reactome epithelial organization and cell-junction pathways are relevant.
- **Interpretation:** The coordinated protective direction of CDX2, CDX1, MYO5B, and epithelial trafficking or differentiation-associated genes suggests that preservation of an intestinal epithelial program may be associated with better OS. This is biologically plausible in colorectal cancer: a supplied literature record reports that CDX2 inhibits colon-cancer proliferation and tumor formation through suppression of Wnt/β-catenin signaling via GSK3β and AXIN2 (PubMed **PMID 30631044**).
- **Evidence strength:** **Supported hypothesis**, because several related epithelial genes point in the same direction and CDX2 has colorectal-specific mechanistic literature.
- **Limitations:** CDX1 and LGALS4 do not meet FDR ≤ 0.05 in the displayed representatives, and the analysis does not establish that the genes are transcriptionally reduced. The apparent program could also reflect tumor differentiation, histologic subtype, or normal epithelial contamination rather than a causal protective mechanism.

### Program 3: Mitochondrial respiration and intermediary metabolism

- **Association:** Mainly protective-associated, although not uniform.
- **Supporting genes:** **ATP23** HR 0.6885, FDR 0.006636; **NDUFA9** HR 0.6886, FDR 0.008647; **CS** HR 0.7545, FDR 0.03875; **COA3** HR 0.7437, FDR 0.04336; **ATP5G1** HR 0.7471, FDR 0.05194; **OGDHL** HR 0.6858, FDR 0.07443; and **GLYCTK** HR 0.7093, FDR 0.02034, **MCCC2** HR 0.739, FDR 0.02823, and **ILVBL** HR 0.7246, FDR 0.03294.
- **Relevant standardized pathways:** Reactome respiratory electron transport and mitochondrial protein-complex assembly; KEGG glycine/serine/threonine metabolism, pentose-phosphate-related metabolism, and central carbon metabolism. The supplied batch also returned glyoxylate and dicarboxylate metabolism.
- **Interpretation:** Multiple mitochondrial and metabolic genes are protective-associated, suggesting that tumors retaining particular oxidative, biosynthetic, or differentiated metabolic features may have better survival. GLYCTK is annotated in glycerate, fructose, and glycine/serine metabolism, while STRING records place it in a predicted or annotated metabolic neighborhood with GRHPR, TKFC, and enolase genes. These records provide network context but do not demonstrate direct interactions among all selected genes.
- **Evidence strength:** **Supported hypothesis** for a metabolic state; **insufficient evidence** for a specific metabolic flux or respiratory mechanism.
- **Limitations:** Survival associations may reflect tumor purity, proliferation, hypoxia, nutritional state, or treatment exposure. The risk-associated **SLC2A3** HR 1.281, FDR 0.07217, and protective-associated **ACSS2** HR 0.7577, FDR 0.06021, indicate that the metabolic pattern is not uniformly oxidative or uniformly glycolytic.

### Program 4: Purinergic and immune-microenvironment signaling

- **Association:** Risk-associated for NT5E; mixed or protective for other immune-related genes.
- **Supporting genes:** **NT5E/CD73** HR 1.313, FDR 0.03939; **LGALS9** HR 0.7533, FDR **0.04204**; **CCL15-CCL14|CCL15** HR 0.7528, FDR 0.0355; **TAPBPL** HR 0.711, FDR 0.01921; and **CCDC134** HR 0.7119, FDR 0.02516.
- **Relevant standardized pathways:** GO regulation of T-cell migration, extracellular purine nucleotide metabolism, adenosine signaling, and immune-cell adhesion/migration.
- **Interpretation:** NT5E is a plausible marker of an immunomodulatory tumor microenvironment because CD73 converts extracellular AMP to adenosine, whereas LGALS9, CCL15, TAPBPL, and CCDC134 may reflect immune interaction, antigen presentation, or tissue-context effects. A literature review record describes CD73/NT5E as a potential cancer-prognostic and immunotherapy biomarker across multiple cancers (PubMed **PMID 36480312**). This supports plausibility but does not establish that CD73-mediated immunosuppression explains the OS association in this cohort.
- **Evidence strength:** **Exploratory to supported hypothesis**, with direct NT5E survival evidence and pathway/literature support but internally mixed immune directions.
- **Limitations:** Bulk tumor RNA cannot distinguish tumor-cell CD73 from endothelial, stromal, or immune-cell expression. The retrieved T-cell-migration annotation is not evidence that T-cell migration was measured. No immune deconvolution, spatial assay, or treatment-response endpoint was supplied.

### Program 5: Cytoskeletal organization, microtubules, and cell motility

- **Association:** Predominantly risk-associated.
- **Supporting genes:** **TPM4** HR 1.364, FDR 0.00891; **NIN** HR 1.345, FDR 0.02823; **MAP1B** HR 1.327, FDR 0.0472; **ABL2** HR 1.301, FDR 0.02757; **GJB6** HR 1.29, FDR 0.03939; and **LRCH1/LRCH3**, with HR 1.337 and 1.341, respectively. LRCH1 is FDR 0.05988, whereas LRCH3 is FDR 0.04062.
- **Relevant standardized pathways:** GO microtubule anchoring at the microtubule-organizing center, actin-filament organization, cell migration, and cytoskeletal regulation.
- **Interpretation:** The convergence of actin-associated TPM4, centrosomal/microtubule-associated NIN and MAP1B, and signaling/adaptor genes is compatible with altered polarity, trafficking, and motility. STRING records connect LRCH1 and LRCH3 to DOCK6, DOCK7, and DOCK8 through a putative cytoskeletal or migration-related neighborhood.
- **Evidence strength:** **Exploratory hypothesis**, supported by multiple risk associations and coherent ontology/network context.
- **Limitations:** STRING relationships can combine physical interaction, co-expression, text mining, and prediction. The supplied records do not establish direct physical interactions among the selected genes, and the analysis does not measure invasion or metastasis.

## 3. Key genes and interaction modules

| Candidate | **Input/uploaded** statistical result | Biological interpretation and relationship type |
|---|---:|---|
| **INHBB** | Risk-associated; HR 1.433, P 1.999e-08, FDR 0.001093 | Top internally supported risk marker; potentially related to TGF-β-family/stromal and invasive biology. |
| **DCBLD2** | Risk representative; HR 1.408, FDR 0.008647; **duplicate-row direction conflict** | Candidate matrix/vascular signaling marker. Interpretation is lower confidence until probe identity and duplicate estimates are resolved. |
| **ITGBL1** | Risk-associated; HR 1.299, P 1.959e-05, FDR 0.03061 | Matrix-associated risk candidate, potentially reflecting tumor–stroma interaction or remodeling. |
| **TPM4** | Risk-associated; HR 1.364, P 1.304e-06, FDR 0.00891 | Strong cytoskeletal risk marker, plausibly related to actin remodeling and motility. |
| **NT5E/CD73** | Risk-associated; HR 1.313, P 4.326e-05, FDR 0.03939 | Candidate immunomodulatory or extracellular-purine biomarker. |
| **CDX2** | Protective-associated; HR 0.7478, P 2.985e-05, FDR 0.0355 | Marker of retained intestinal differentiation and a candidate prognostic biomarker. |
| **MYO5B** | Protective-associated; HR 0.7483, P 1.607e-05, FDR 0.02823 | Epithelial trafficking/polarity candidate that complements the CDX1/CDX2 differentiation signal. |
| **ATP23–NDUFA9–CS/COA3 module** | ATP23 HR 0.6885, FDR 0.006636; NDUFA9 HR 0.6886, FDR 0.008647; CS and COA3 also protective at FDR ≤ 0.05 | Protective mitochondrial module; the shared interpretation is pathway co-membership, not proof of a physical complex or coordinated flux. |
| **GLYCTK–MCCC2–ILVBL–ASL module** | All protective-associated at FDR ≤ 0.05 | Intermediary-metabolism candidate module. STRING links are database network associations, not direct interactions established in this dataset. |
| **LRCH1–LRCH3–DOCK neighborhood** | LRCH1 HR 1.337, FDR 0.05988; LRCH3 HR 1.341, FDR 0.04062 | Possible risk-associated motility/network module; direct physical binding is insufficiently evidenced. |

The literature record for **LINC00852** should not be used to strengthen the present result: the **input/uploaded** colorectal dataset shows a protective-associated estimate, HR 0.741, but FDR 0.07206, whereas the cited study concerns poor prognosis in non-small-cell lung cancer (PMID 34342374). This is tissue- and significance-level discordant contextual evidence, not **external/independent** validation.

## 4. Validation priorities

### 1. Validate an INHBB-centered invasive/stromal mechanism  
**Classification:** Mechanistic hypothesis

INHBB is the strongest risk-associated gene in the **input/uploaded** table, with HR 1.433 and FDR 0.001093, and is supported by colorectal-cancer literature. The next step is validation in an **external/independent** CRC cohort with multivariable adjustment for stage, grade, MSI status, treatment, and tumor purity, followed by perturbation studies in CRC organoids or fibroblast co-culture. This remains a **supported hypothesis**, not established causality.

### 2. Test whether epithelial differentiation is a protective prognostic state  
**Classification:** Biomarker

CDX2, CDX1, MYO5B, LGALS4, and RAB11FIP4 form a biologically coherent protective pattern in the **input/uploaded** data. CDX2 and MYO5B meet FDR ≤ 0.05; CDX1 and LGALS4 are directionally concordant but above that threshold. An epithelial-differentiation score should be prespecified and tested in **external/independent** bulk and single-cell CRC cohorts.

### 3. Determine whether NT5E reflects tumor-cell or microenvironmental immunoregulation  
**Classification:** Biomarker / confounding or composition check

NT5E is risk-associated in the **input/uploaded** cohort, HR 1.313 and FDR 0.03939, whereas immune-context genes show mixed directions. Single-cell or spatial transcriptomics, multiplex immunohistochemistry, immune deconvolution, and stratification by MSI, immune-checkpoint treatment, and stage are required. The CD73 literature supports plausibility but is not **external/independent** CRC survival replication.

### 4. Validate a mitochondrial/intermediary-metabolism prognostic module  
**Classification:** Mechanistic hypothesis

ATP23 and NDUFA9 are among the most statistically robust protective genes in the **input/uploaded** ledger, with additional support from CS, COA3, GLYCTK, MCCC2, ILVBL, and ASL. The module should be tested in an **external/independent** cohort and then evaluated with metabolic assays or perturbation experiments. The current data support a prognostic metabolic-state hypothesis but do not establish a specific respiratory pathway or metabolic flux.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=106, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
